Table 2.
Therapeutic strategies to target inflammasome in cigarette smoke-induced diseases and physiopathological disorders.
| Reference | Year | Disease/disorder | Therapy | Mechanism |
|---|---|---|---|---|
| Wu et al. (41) | 2018 | Atherosclerosis | NAC | Inhibit ROS |
| Wu et al. (44) | 2020 | Bladder damage | NAC | Inhibit ROS |
| Singh et al. (46) | 2019 | Podocyte injury | NAC | Scavenge ROS |
| Wang et al. (49) | 2019 | Endothelial dysfunction | Melatonin | Inhibit ROS/NLRP3 axis |
| Mahalanobish et al. (21) | 2020 | COPD | Melatonin | Suppress endoplasmic reticulum stress, mitochondrial dysfunction and further inhibit NLRP3 inflammasome activation |
| Wang et al. (27) | 2019 | COPD | Transient receptor potential protein ion channel inhibitors | Reduce oxidative stress, block Ca2+ influx, and inhibit NLRP3 inflammasome activation |
| Yao et al. (42) | 2019 | Arteriosclerosis | Rosmarinic acid | Inhibit the ROS-NLRP3 inflammasome-CRP axis |
| Cao et al. (29) | 2018 | COPD | Lipoxin receptor agonist | Inhibit ROS production and prevent NLRP3 inflammasome activation |
| Ji et al. (24) | 2020 | AECOPD | Shufeng Jiedu Capsule (SFJDC), oseltamivir | Inhibit NLRP3 inflammasome activation |
| Zhang et al. (47) | 2019 | Endothelial barrier dysfunction | Blockade of HMGB1 | Inhibit NLRP3 inflammasome activation |
| Chen et al. (48) | 2019 | Endothelial barrier dysfunction | Mitoquinone | Inhibit NLRP3 inflammasome activation |
| Zhang et al. (39) | 2018 | ALI | Suppressor of cytokine signaling-1 (SOCS-1) | Dampen the formation of NLRP3 inflammasome and the activation of caspase-1 and IL-1β |
| Singh et al. (31) | 2018 | COPD | Poly-unsaturated fatty acids (PUFA) | Inhibit membrane recruitment of NLRP10 and NLRP12 |
NAC, N, Acetyl, L, cysteine; ROS, reactive oxygen species; NLRP, nucleotide binding oligomerization domain and leucine, rich repeat containing receptor; COPD, chronic obstructive pulmonary disease; CRP, C reactive protein; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; HMGB1, high mobility group box 1; ALI, acute lung injury; IL, interleukin.